Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 453,418,112
  • Shares Outstanding, K 2,633,396
  • Annual Sales, $ 82,584 M
  • Annual Income, $ 14,714 M
  • 60-Month Beta 0.71
  • Price/Sales 5.49
  • Price/Cash Flow 15.81
  • Price/Book 6.91
Trade JNJ with:

Options Overview

Details
  • Implied Volatility 14.93%
  • Historical Volatility 10.68%
  • IV Percentile 9%
  • IV Rank 6.72%
  • IV High 33.44% on 10/30/20
  • IV Low 13.59% on 06/10/21
  • Put/Call Vol Ratio 0.53
  • Today's Volume 12,216
  • Volume Avg (30-Day) 31,217
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 416,951
  • Open Int (30-Day) 424,331

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 2.38
  • Number of Estimates 6
  • High Estimate 2.56
  • Low Estimate 2.26
  • Prior Year 2.20
  • Growth Rate Est. (year over year) +8.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
164.63 +4.60%
on 07/01/21
173.38 -0.68%
on 07/28/21
+7.46 (+4.53%)
since 06/30/21
3-Month
161.79 +6.43%
on 06/18/21
173.38 -0.68%
on 07/28/21
+9.47 (+5.82%)
since 04/30/21
52-Week
133.65 +28.84%
on 10/30/20
173.65 -0.84%
on 01/26/21
+25.36 (+17.27%)
since 07/30/20

Most Recent Stories

More News
The Latest: Georgia scrambles to increase vaccination rates

ATLANTA — Local officials in Georgia are scrambling to increase vaccination rates even as more schools continue telling students and employees to wear masks in the face of rising COVID-19 infection rates....

JNJ : 172.20 (+0.01%)
AbbVie's (ABBV) Q2 Earnings In Line, 2021 Guidance Raised

AbbVie (ABBV) matches second-quarter 2021 earnings estimates while beating the same for sales. Sales of new immunology drugs, Skyrizi and Rinvoq, reach $1 billion.

RHHBY : 48.2600 (+1.05%)
JNJ : 172.20 (+0.01%)
AMGN : 241.54 (-0.38%)
ABBV : 116.30 (-2.16%)
Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit

Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.

AZN : 57.24 (-0.69%)
JNJ : 172.20 (+0.01%)
CDXS : 21.16 (-0.80%)
EBS : 65.90 (+1.04%)
Virpax(R) Pharmaceuticals Strengthens Board of Directors with the Appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board

Virpax(R) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing pharmaceutical product candidates for pain management, today announced the appointment of...

VRPX : 4.45 (-1.33%)
JNJ : 172.20 (+0.01%)
BMY : 67.87 (-0.41%)
Pharma & Healthcare ETFs at a One-Year High: Here's Why

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

JNJ : 172.20 (+0.01%)
PFE : 42.81 (+0.05%)
MRNA : 353.60 (+2.30%)
PJP : 81.16 (-0.79%)
IHE : 191.72 (-0.39%)
PPH : 74.86 (-0.45%)
FXH : 122.05 (+0.26%)
IEIH : 35.78 (-0.48%)
The Latest: US health officials to release new COVID-19 data

NEW YORK -- U.S. health officials are expected to release new data about the spread of COVID-19 on Friday that led to their decision to recommend that vaccinated people wear masks in some situations, a...

JNJ : 172.20 (+0.01%)
ADBE : 621.63 (-0.01%)
KR : 40.70 (-0.05%)
Emergent: FDA letting troubled COVID vaccine factory restart

The U.S. Food and Drug Administration is allowing the problem-plagued factory of contract manufacturer Emergent BioSolutions to resume production of COVID-19 vaccine, the company said Thursday.

JNJ : 172.20 (+0.01%)
Women Cancer Victims Opposed to Johnson & Johnson's 'Texas Two-Step' Bankruptcy Ploy Urge Passage of Reforms Introduced by Warren, Durbin, Nadler, Blumenthal, and Maloney

/PRNewswire/ -- More than 30,000 women cancer victims would retain their constitutional right to have juries decide if talc in Johnson & Johnson's (NYSE:JNJ) baby products caused their ovarian cancer under...

JNJ : 172.20 (+0.01%)
Glaxo's (GSK) Q2 Earnings Beat, Revenues on Recovery Track

Glaxo's (GSK) revenues benefit from recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.

GSK : 40.14 (+0.10%)
JNJ : 172.20 (+0.01%)
PFE : 42.81 (+0.05%)
VIR : 35.65 (-2.03%)
US extends expiration dates on J&J COVID vaccine to 6 months

WASHINGTON (AP) — Federal health regulators on Wednesday again extended the expiration dates on Johnson & Johnson's COVID-19 vaccine, providing health workers with six more weeks to use millions of doses...

JNJ : 172.20 (+0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

3rd Resistance Point 173.98
2nd Resistance Point 173.48
1st Resistance Point 172.84
Last Price 172.20
1st Support Level 171.70
2nd Support Level 171.20
3rd Support Level 170.56

See More

52-Week High 173.65
Last Price 172.20
Fibonacci 61.8% 158.37
Fibonacci 50% 153.65
Fibonacci 38.2% 148.93
52-Week Low 133.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar